Premium
Comparison of the short‐term efficacy and serum markers between lobaplatin/paclitaxel‐ And carboplatin/paclitaxel‐based adjuvant chemotherapy in patient with ovarian cancer
Author(s) -
Wang Wei,
Liu Ming,
Ding Boyong
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13276
Subject(s) - carboplatin , medicine , paclitaxel , ovarian cancer , chemotherapy , therapeutic effect , cisplatin , adjuvant , oncology , gastroenterology , cancer
Abstract What is known and objective To compare short‐term therapeutic efficacies and related changes of serum markers from two chemotherapeutic regimes using lobaplatin or carboplatin in combination with paclitaxel in ovarian cancer patients after cytoreductive surgery. Methods 120 patients were recruited with pathologically confirmed ovarian cancer. Patients were equally and randomly divided into two groups receiving paclitaxel (PTX) with lobaplatin (LBP) or carboplatin (CBP, as control), respectively, 21 days as a cycle for 6 cycles. Follow‐up was performed for 6 months post‐treatment. The therapeutic efficacy, serum levels of CA125 (cancer antigen 125/ mucin 16) and HE4 (Human epididymis protein 4) as well as the quality of life were assessment before and after treatment. Results No significant difference in therapeutic efficacy was observed between the groups ( P > .05). The response rates at 1, 3 and 6 months were 76.7%, 66.7% and 46.7% in the LBP group and 73.3%, 63.3% and 36.7% in the CPB group, respectively. At the end of chemotherapy, serum levels of HE4 and CA125 in both groups returned to normal. However, patients in the LBP group had significantly lower HE4 and CA125 levels than those in the CPB group when examined at 3 or 6 months after chemotherapy ( P < .05). Moreover, at the end of follow‐up, the quality‐of‐life score (QLQ‐C30) of the LBP group was better than that of the CBP group with statistical significance ( P < .05). What is new and conclusion Both lobaplatin and carboplatin have decent anti‐tumour efficacy to be involved in the standard platinum/paclitaxel‐based chemotherapy against ovarian cancer. Lobaplatin, on the other hand, has demonstrated higher efficacy to control the progress of the disease yet less toxicity to warrant better patient quality of life.